Who Owns Retina Consultants of America?

RCA's sustainability and ethics practices fall under two frameworks: its own physician-led governance model and Cencora's corporate ESG framework.

Physician-Led Governance: RCA's core ethical principle is that clinical decisions remain in the hands of practicing physicians. The organization's physician-centered model means that retina specialists drive clinical care and practice culture, while RCA provides business support. This structure is designed to prevent corporate interests from influencing medical decision-making, a concern that has been raised about private equity and corporate ownership of medical practices. The minority equity retention by physicians following the Cencora acquisition reinforces this principle by giving physicians an ownership stake in the organization's success.

Clinical Research Ethics: RCA Research operates 40 clinical trial sites with 400 full-time research employees, conducting Phase I-IV trials for new retinal treatments. The organization's research activities are subject to Institutional Review Board (IRB) oversight, informed consent requirements, and FDA clinical trial regulations. RCA's participation in clinical trials gives patients access to experimental treatments that may not be available through standard care, while contributing to the advancement of retinal disease treatment.

Cencora ESG Framework: As part of Cencora, RCA's environmental and social sustainability practices fall under Cencora's corporate responsibility framework. Cencora has set Scope 1 and 2 emissions reduction targets and has invested in renewable energy including solar photovoltaic installations at facilities in Sweden, Switzerland, and Denmark. Cencora's headquarters in Conshohocken, Pennsylvania, has LEED Gold certification. However, RCA's direct environmental footprint is relatively small since it operates as a management services organization rather than a manufacturing or distribution operation.

Healthcare Access: RCA's network of nearly 300 retina specialists across 23 states provides patient access to specialized retinal care that might otherwise be unavailable in certain geographic markets. The organization's scale enables it to support practices in smaller markets that might struggle independently, helping to maintain access to retina specialty care outside major metropolitan areas.

Cencora does not hold B Corp certification. The company publishes an annual corporate responsibility report covering ESG metrics across its operations.

RCA's recognition comes primarily from its clinical research contributions and the professional recognition of its affiliated physicians:

• Dr. Kevin J. Blinder from The Retina Institute (TRI), an RCA partner practice, received the American Society of Retina Specialists (ASRS) 2025 Packo Award in recognition of his exceptional service to the Society and contributions to retina specialty care.
• RCA Research operates one of the largest retina-specific clinical trial networks in the United States, with 40 Phase I-IV clinical trial sites and 400 dedicated full-time research employees. The division has been recognized within the ophthalmology research community for its contributions to advancing retinal treatment options.
• RCA's affiliated physicians frequently hold leadership positions in professional ophthalmology associations including the American Society of Retina Specialists (ASRS), the American Academy of Ophthalmology (AAO), and the Retina Society. These leadership roles reflect the clinical expertise within RCA's network.
• RCA practices conduct over 2 million patient visits annually, treating retinal diseases including age-related macular degeneration, diabetic retinopathy, retinal detachment, and retinal vein occlusion. The organization's scale makes it one of the largest providers of retina specialty care in the United States.
• The Cencora acquisition valued RCA at approximately $4.6 billion, reflecting the organization's growth from a $350 million platform in 2020 to one of the most valuable physician management organizations in ophthalmology within five years.

No Product Recalls: As a physician management services organization, RCA is not subject to product recalls. The organization does not manufacture or distribute medical products directly. Pharmaceutical products used in RCA-affiliated practices are subject to FDA regulation and any recalls are handled by the pharmaceutical manufacturers.

Healthcare Consolidation Concerns: RCA's acquisition by Cencora reflects a broader trend of consolidation in healthcare that has drawn scrutiny from regulators and patient advocates. Some observers have raised concerns about pharmaceutical distributors acquiring medical practice management organizations, citing potential conflicts of interest or influence on clinical decision-making. However, RCA's physician-led model, in which clinical decisions remain with practicing physicians, has been cited as a positive example of maintaining clinical independence within a larger corporate structure.

Acquisition Integration: Following the January 2025 acquisition, RCA faced integration challenges common to large healthcare mergers, including aligning RCA's physician-led culture with Cencora's corporate structure. The acquisition structure, which allowed physicians and management to retain minority equity interests, was designed to mitigate cultural conflicts. As of 2026, the integration appears to be proceeding without major public disputes.

Private Equity Healthcare Concerns: RCA's formation by Webster Equity Partners in 2020 and subsequent sale to Cencora in 2025 for a significant premium reflects the broader trend of private equity investment in healthcare practices. Some healthcare policy experts have raised concerns that private equity ownership of medical practices can lead to cost increases, reduced physician autonomy, and prioritization of financial returns over patient care. RCA's physician-centered model was designed in part to address these concerns by maintaining clinical autonomy for affiliated physicians.

Regulatory Compliance: RCA operates under extensive regulatory oversight from the Centers for Medicare & Medicaid Services (CMS), state medical boards, and other healthcare regulators. The organization must comply with the Stark Law (physician self-referral law), the Anti-Kickback Statute, and other healthcare fraud and abuse laws that govern the relationship between management services organizations and physician practices. No specific regulatory enforcement actions against RCA have been publicly documented.